Loading clinical trials...
Loading clinical trials...
Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19
Conditions
Interventions
intermediate dose Enoxaparin/ unfractionated heparin
standard prophylactic dose Enoxaparin/ unfractionated heparin
+2 more
Locations
1
Iran
Masih Daneshvari Hospital
Tehran, Iran
Start Date
July 30, 2020
Primary Completion Date
April 4, 2021
Completion Date
July 5, 2021
Last Updated
August 17, 2021
NCT04525716
NCT03188796
NCT06355232
NCT05191420
NCT04611243
NCT04678193
Lead Sponsor
Rajaie Cardiovascular Medical and Research Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions